Ondine Biomedical (LON:OBI) Hits New 52-Week High – Should You Buy?

Ondine Biomedical Inc. (LON:OBI) shares reached a new 52-week high on Thursday . The company traded as high as GBX 12.50 ($0.15) and last traded at GBX 12 ($0.15), with a volume of 314113 shares trading hands. The stock had previously closed at GBX 11.50 ($0.14).

Ondine Biomedical Stock Up 4.3 %

The stock has a market capitalization of £33.27 million, a P/E ratio of -400.00 and a beta of 0.10. The stock’s 50-day moving average price is GBX 8.63 and its two-hundred day moving average price is GBX 7.79. The company has a current ratio of 0.80, a quick ratio of 8.26 and a debt-to-equity ratio of 1,847.37.

Ondine Biomedical Company Profile

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens.

Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings.